These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 26976984)

  • 1. A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women.
    Leandersson P; Kalapotharakos G; Henic E; Borgfeldt H; Petzold M; Høyer-Hansen G; Borgfeldt C
    Anticancer Res; 2016 Mar; 36(3):957-65. PubMed ID: 26976984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
    Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
    PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.
    Fujiwara H; Suzuki M; Takeshima N; Takizawa K; Kimura E; Nakanishi T; Yamada K; Takano H; Sasaki H; Koyama K; Ochiai K
    Tumour Biol; 2015 Feb; 36(2):1045-53. PubMed ID: 25326813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
    Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
    Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
    Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
    Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.
    Bandiera E; Romani C; Specchia C; Zanotti L; Galli C; Ruggeri G; Tognon G; Bignotti E; Tassi RA; Odicino F; Caimi L; Sartori E; Santin AD; Pecorelli S; Ravaggi A
    Cancer Epidemiol Biomarkers Prev; 2011 Dec; 20(12):2496-506. PubMed ID: 22028406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic performance of human epididymis protein 4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women.
    Nikolova T; Zivadinovic R; Evtimovska N; Klisarovska V; Stanojevic M; Georgievska J; Nikolova N
    J Obstet Gynaecol Res; 2017 Dec; 43(12):1870-1879. PubMed ID: 29027715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
    Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
    Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China.
    Xu Y; Zhong R; He J; Ding R; Lin H; Deng Y; Zhou L; Li X; Jiang J; Bao Y; Luo X; Duan C
    Clin Biochem; 2016 Jan; 49(1-2):32-40. PubMed ID: 26285075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass.
    Chan KK; Chen CA; Nam JH; Ochiai K; Wilailak S; Choon AT; Sabaratnam S; Hebbar S; Sickan J; Schodin BA; Sumpaico WW
    Gynecol Oncol; 2013 Feb; 128(2):239-44. PubMed ID: 23063998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women.
    Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y
    Tumour Biol; 2016 Feb; 37(2):2183-91. PubMed ID: 26349751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
    Wang Z; Tao X; Ying C
    Dis Markers; 2019; 2019():6241743. PubMed ID: 31737130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
    Lycke M; Kristjansdottir B; Sundfeldt K
    Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
    Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
    Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.
    Li F; Tie R; Chang K; Wang F; Deng S; Lu W; Yu L; Chen M
    BMC Cancer; 2012 Jun; 12():258. PubMed ID: 22712526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
    Montagnana M; Danese E; Ruzzenente O; Bresciani V; Nuzzo T; Gelati M; Salvagno GL; Franchi M; Lippi G; Guidi GC
    Clin Chem Lab Med; 2011 Mar; 49(3):521-5. PubMed ID: 21288178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.